Clinical trial
A Phase III, Double-blind, Randomized, Parallel Group, Placebo-controlled Study of Oral Fosamax, 70 mg Once a Week, for the Prevention of Androgen Deprivation Bone Loss in Non-metastatic Prostate Cancer
NCT00236002 is registered in ClinicalTrials.gov with Canadian Urology Research Consortium as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Double-blind, Randomized, Parallel Group, Placebo-controlled Study of Oral Fosamax, 70 mg Once a Week, for the Prevention of Androgen Deprivation Bone Loss in Non-metastatic Prostate Cancer
- Lead sponsor
- Canadian Urology Research Consortium
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- July 31, 2005
- Completion date
- August 31, 2009
- Enrollment
- 182 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.